The partnership offers a full suite of assay services to biopharma customers from both companies. Credit: Tatiana from Pixabay.

Japan-based Sysmex’s subsidiary Sysmex Inostics has entered a strategic partnership with US-based Genomic Testing Cooperative (GTC) to advance therapeutic discovery and development.

The partnership will focus on the commercialisation of GTC’s tissue and liquid biopsy solid tumours as well as haematology assay services to biopharma customers.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The genomic tests to be commercialised under the partnership include GTC’s Solid Tumor Profile Plus, Liquid Trace Hematology Profile, Liquid Trace Solid Tumor Profile and Hematology Profile Plus.

Sysmex Inostics will provide customers with GTC’s tissue and liquid biopsy assay services along with its own products and services.

GTC’s portfolio covers several modalities such as chromosomal abnormalities, tumour cell of origin, RNA expression and immunophenotyping, tumour mutation burden, homologous recombination deficiency, exon skipping and levels of EBV and HPV viral RNA.

GTC’s technology in artificial intelligence, genomic databases and DNA and RNA next-generation sequencing profiling will leverage Sysmex’s global commercial capabilities in biopharma therapeutic development and Plasma-Safe-SeqS technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GTC CEO and chief medical officer Maher Albitar said: “The alliance with Sysmex Inostics is fundamental to our mission of democratising genomic testing and making it available and affordable to every patient dealing with cancer.”

The partnership offers a full suite of assay services to biopharma customers to support all phases of the clinical trial process.

GTC and Sysmex Inostics will also work together on improvements and new indications of the tests to enhance their offers for biopharma researchers.

Sysmex Inostics president and CEO Shinichi Sato said: “We understand not one testing solution fits all stages of therapeutic development and it was imperative to offer our biopharma partners GTC’s broader panels for their discovery work.”